In a surprising move, Rentschler Biopharma announced its decision to withdraw from the cell and gene therapy (CGT) business at its Stevenage, UK facility, marking a significant shift in the company's strategic focus. This decision comes despite recent investments in building advanced capabilities
Basal cell carcinoma (BCC) is the most common cancer worldwide, with its incidence doubling over the past 20 years. Traditional treatments, primarily surgical excision, come with a recurrence risk and potential complications. This article explores the potential of Talimogene laherparepvec (T-VEC),
A significant breakthrough in vaccine development has been achieved by a collaboration between the Ragon Institute and the Jameel Clinic at MIT, as they unveil MUNIS, a deep learning tool designed to accurately predict CD8+ T cell epitopes. This innovative tool promises to accelerate vaccine
Sphere Fluidics has made strides in biotechnology by unveiling its innovative Cyto-Mine® Chroma at the SLAS2025 International Conference and Exhibition recently held in San Diego, California. This cutting-edge iteration of their well-established Cyto-Mine platform is primed to revolutionize
Every 40 seconds, someone in the United States experiences a stroke, and ischemic strokes are the most common type. Unfortunately, only about 5% of ischemic stroke survivors fully recover, while many endure long-term complications such as weakness, chronic pain, or epilepsy. Given these concerning
The field of cell therapy is currently witnessing groundbreaking advancements, particularly in the methods of stem cell collection and the automation of manufacturing processes. These innovations hold the potential to revolutionize the sector by significantly enhancing the efficiency, reliability,
